Switch to DRV/r + RAL
SPARE Study
Original article : PLoS One. 2013 Aug 8;8(8) - T Nishijima
Dernière mise à jour :
18/07/2016
Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK
- Switching LPV/r + TDF/FTC to RAL+ DRV/r did not significantly increase the proportion of patients who showed >10% improvement in renal function among those with relatively preserved eGFR . However, the switch improved urinary β2 microglobulin , suggesting that discontinuation of TDF might be beneficial in the long-term
- RAL +DRV/r showed favorable viral efficacy in patients with suppressed viral load
- Limitations
- Small sample size
- Adverse events self-reported, open-label unblinded design
Design
* Randomisation was stratified based on baseline body weight of 60 kg
Objective
- Primary endpoint: proportion of patients with > 10% improvement in eGFR at 48 weeks from the baseline calculated with the CG equation
- Secondary endpoints: changes in per protocol renal tubular markers from baseline to week 48, proportions of patients with HIV-1 RNA < 50 c/mL at W24 and W48 (per protocol and ITT)
Baseline characteristics (mean), and disposition
Endpoints by W48
Back to Table of Contents
Download the slides
